Long-term use of 5-alpha-reductase inhibitors is safe and effective in men on active surveillance for prostate cancer

Although 5-alpha-reductase inhibitors (5ARIs) have been shown to benefit men with prostate cancer (PCa) on active surveillance (AS), their long-term safety remains controversial. The objective of this article is to describe the long-term association of 5ARI use with PCa progression in men on AS.